NCT07321574 2026-01-07
ABP1011T-03
Shanghai AB PharmaTech Ltd.
Phase 2 Recruiting
Clinical Trials
3 trialsNCT06812260 2025-09-17
A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 2 Recruiting
NCT05116007 2024-05-31
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Akeso
Phase 1 Completed